XENE - Xenon Pharmaceuticals Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Xenon Pharmaceuticals Inc.

200 - 3650 Gilmore Way
Burnaby, BC V5G 4W8

Full Time Employees89

Key Executives

NameTitlePayExercisedYear Born
Dr. Simon N. PimstoneCEO & Director679.72kN/A1968
Mr. Ian C. Mortimer C.M.A., CPA, M.B.A., MBA, CPA, CMAPres, CFO, COO & Company Sec.558.58kN/A1976
Mr. Ernesto Aycardi-Fonseca M.D.Chief Medical Officer609.08kN/A1963
Ms. Jodi Regts M.B.A., B.A., MBAVP of Corp. Affairs & Investor RelationsN/AN/AN/A
Ms. Shelley McCloskeySr. VP of HRN/AN/A1960
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline include XEN496, A Kv7 potassium channel modulator that is phase II clinical trials for the treatment of KCNQ2 epilepsy; XEN1101, A Kv7 potassium channel modulator, which is in phase II clinical trail for the treatment of epilepsy. The company's product candidates also comprise XEN901, a selective Nav1.6 sodium channel inhibitor that is in phase I clinical trials for the treatment of epilepsy; and XEN007, A central nervous system-acting calcium channel modulator, which is in phase I clinical trials. The company was founded in 1996 and is headquartered in Burnaby, Canada.

Corporate Governance

Xenon Pharmaceuticals Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.